A Retrospective Analysis of the Efficacy of Ceftriaxone-Sulbactam-EDTA Combination for Suspected Biofilm Infections
Journal Title: National Journal of Laboratory Medicine - Year 2019, Vol 8, Issue 1
Abstract
ABSTRACT Introduction: Bacterial biofilms are highly recalcitrant to antibiotic treatment and thus carry important clinical repercussions. In view of rising biofilm-forming pathogens, new antibacterial approaches aimed at disrupting biofilms are needed. Aim: To determine the clinical utility of CSE-1034 (Ceftriaxone-Sulbactam-EDTA) therapy in suspected biofilm infections. Materials and Methods: Subjects with Urinary Tract Infections (UTIs) or Intra-Abdominal Infections (IAIs) with in-vivo devices (catheters, stents, etc.,) and suspected of biofilm-related infections and who received CSE-1034 as 2nd line therapy were included in this study. Based on susceptibility report, CSE-1034 therapy was started in these patients and continued or discontinued based on improvement in clinical symptoms. Results: Thirty culture-positive adult patients were included in this study. All the patients had received Pipericillin-Tazobactam (Pip-Taz) or Cefaperazone-Sulbactam empirically but none of them responded clinically. Culture susceptibility results available on day 3 have shown that isolates from 40% patients started with Pip-Taz were reported susceptible to Pip-Taz and 45% of patients started with Cefaperazone-Sulbactam were reported susceptible to antibiotic used. 100% of the isolates were susceptible to CSE-1034, 90% to Meropenem and susceptibility to Colistin was 80%. Based on culture susceptibility report and further treatment modifications done, all the patients were switched over to CSE-1034 as 2nd line treatment. A total of 27 patients responded to CSE-1034 and were cured. However, 3 patients who did not respond to CSE-1034 for 48 hour were switched over to Meropenem and reported to be cured. Conclusion: From this study, it can be suggested that CSE-1034 should be a choice of treatment over beta-lactam/beta-lactam inhibitor combinations for patients suspected of biofilm infections.
Authors and Affiliations
Sunita Gupta, Taranpreet Kaur
Keywords
Related Articles
- EP ID EP609990
- DOI 10.7860/NJLM/2019/36849:2338
- Views 134
- Downloads 0
A Study of Thyroid Profile in Patients with Psoriasis
Introduction: With a prevalence of 2% in Europe and North America, psoriasis is a common disease, showing a linear increase of prevalence over time, with prevalence at the age of 18 years comprising around 1%. Associated...
Evaluation of Nested PCR for Rapid Diagnosis of Pediatric Tuberculous Meningitis
Introduction: Pediatric Tuberculous Meningitis (TBM) is a highly morbid, often fatal disease and its prompt diagnosis is fundamental to the proper management. Cerebrospinal fluid (CSF) is paucibacillary in such cases and...
Prevalence of Rotavirus Diarrhoea in Children in Davangere, Karnataka
Introduction: Rotavirus was described 40 years back, yet it is recognized as the leading cause of diarrhoeal morbidity and mortality, particularly in children in developing countries. In India, rotavirus infection accoun...
AIDS Dementia Complex with Tinea Faciei with Very Low CD4 Count: An Unusual Case Report
ABSTRACT Dermatophyte infections are common in HIV infected patients and can occur at some point during their illness but Tinea faciei not a common presentation in adults, although a few cases have been described in HIV-...
Role of Line Probe Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Drug Resistance Directly from Clinical Samples
ABSTRACT Introduction: The global burden of Multi Drug Resistant Tuberculosis (MDR TB) is increasing worldwide. Smear microscopy has low sensitivity, culture based tests for identification of tubercle bacilli and drug su...